AbbVie Inc. (ABBV)
NYSE · North Chicago, Illinois, USA · Founded 2013 · CEO Robert Michael
Valuation summary
$177.11 fair value versus $283.54 in the market, a difference of -37.5%. Rated Sell.
| Fair value per share | $177.11 |
| Current share price | $283.54 |
| Upside / downside | -37.5% |
| Bear case | $106.94 |
| Bull case | $277.61 |
| Discount rate (WACC) | 8.4% |
| Terminal growth | 2.50% |
| Market capitalisation | $501B |
| EV / Sales | 8.7x |
About AbbVie Inc.
Spun out of Abbott Laboratories in 2013 to separate the research pharmaceutical business. Robert Michael became CEO in 2024. AbbVie is built around immunology: Skyrizi and Rinvoq, the two successors to Humira, which was for years the best-selling drug in the world before losing exclusivity in 2023. In September 2026 it completed the $10.9B cash acquisition of Apogee Therapeutics, adding zumilokibart, a late-stage IL-13 antibody for atopic dermatitis. It also owns Botox and the Allergan aesthetics portfolio, oncology assets including Imbruvica and Venclexta, and a neuroscience franchise with Vraylar and Ubrelvy, joined in September 2026 by Juvmo (tavapadon) for Parkinson's disease. The stock rose 11.15% in the week to 21 July 2026.
Investment case
- Skyrizi and Rinvoq have more than replaced Humira revenue, which is the hardest transition in pharma and AbbVie executed it.
- Aesthetics and Botox provide a cash-pay revenue stream insulated from drug pricing politics.
- One of the highest dividend yields among large-cap pharma with a strong coverage ratio.
Key risks
- Net debt above $60B from the Allergan acquisition is high relative to peers.
- The immunology category is crowded and biosimilar pressure eventually reaches Skyrizi and Rinvoq too.
- Aesthetics demand is discretionary and softened when consumers tightened spending.
Recent developments
- 2026-10-30 · Q3 revenue up 10.3% to $17.4bn as Skyrizi ($5.78bn) and Rinvoq ($2.71bn) each grow over 22%; 2026 adjusted EPS guide raised to $13.95-$13.99 source
- 2026-09-28 · FDA approved Juvmo (tavapadon), the first selective D1/D5 agonist for Parkinson's disease, as monotherapy or with levodopa; US availability expected October 2026. source
- 2026-09-03 · AbbVie completed its $10.9B acquisition of Apogee Therapeutics at $135.11 per share in cash, adding the late-stage IL-13 antibody zumilokibart. source
Revenue by segment
| Immunology | 47% |
| Neuroscience | 16% |
| Oncology | 14% |
| Aesthetics | 13% |
| Other | 10% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $72.9B | $16.6B |
| Year 2 | $80.4B | $18.0B |
| Year 3 | $88.5B | $19.4B |
| Year 4 | $97.0B | $20.8B |
| Year 5 | $106.2B | $22.3B |
What the street says
Generally viewed favourably on the strength of the Humira transition. The Apogee acquisition and the September 2026 approval of Juvmo in Parkinson's disease are the latest answers to the question of what sustains growth into the 2030s.
Comparable companies: TMO · JNJ · AMGN · GILD · ABT · MDT · SNY · AZN
Open the interactive model, price chart and sensitivity grid →